Literature DB >> 25664037

Poly-l-lactic acid/amorphous calcium phosphate bioabsorbable stent causes less inflammation than poly-l-lactic acid stent in coronary arteries.

Lingting Kong1, Wenbo Liu2, Ge Yan3, Qiang Li2, Haiyan Yang1, Fengxia Yu1, Haoming Song4.   

Abstract

AIM: Poly-l-lactic acid (PLLA) based bioabsorbable stents with or without amorphous calcium phosphate (ACP) were implanted and compared the inflammation in coronary arteries.
METHODS: 6 PLLA and 6 PLLA/ACP based paclitaxel-eluting stents were randomly implanted into the coronary arteries of 12 healthy mini-pigs. The segments with stent were used to evaluate inflammation score and endothelialization score by hematoxylin-eosin staining.
RESULTS: At the 28th day after stent implantation, no in-stent restenosis or stent thrombosis was found in both PLLA and PLLA/ACP group. Histological analysis indicated that the inflammation score in PLLA/ACP group was less than that of in PLLA group (2.20±0.42 vs. 2.80±0.48, P<0.05). Consist with that, the expression of NF-κB was lower in PLLA/ACP group. The results from immunohistochemistry showed that the expressions of endothelial nitric oxide synthase (eNOS) and CD 31 in PLLA/ACP group were dramatically higher than those in PLLA group respectively. The serum levels of vascular endothelial growth factor (VEGF) and nitric oxide (NO) in PLLA/ACP group were significantly higher than those in PLLA group respectively (509.86±49.37 pg/ml vs. 322.04±35.16 pg/ml and 139.46±7.52 μmol/L vs. 29.55±16.55 μmol/L, P<0.05).
CONCLUSION: The application of ACP helps to reduce the inflammation caused by PLLA, and is also helpful in endothelial formation and function for PLLA-based bioabsorbable stent.

Entities:  

Keywords:  Poly-l-lactic acid; amorphous calcium phosphate; bioabsorbable stent; inflammation

Year:  2014        PMID: 25664037      PMCID: PMC4307484     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  17 in total

Review 1.  Amorphous calcium phosphates: synthesis, properties and uses in biomaterials.

Authors:  C Combes; C Rey
Journal:  Acta Biomater       Date:  2010-02-16       Impact factor: 8.947

2.  Emerging thrombotic effects of drug eluting stents.

Authors:  Ninian N Lang; David E Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02       Impact factor: 8.311

3.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.

Authors:  Patrick W Serruys; John A Ormiston; Yoshinobu Onuma; Evelyn Regar; Nieves Gonzalo; Hector M Garcia-Garcia; Koen Nieman; Nico Bruining; Cécile Dorange; Karine Miquel-Hébert; Susan Veldhof; Mark Webster; Leif Thuesen; Dariusz Dudek
Journal:  Lancet       Date:  2009-03-14       Impact factor: 79.321

4.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Authors:  Matthias Pfisterer; Hans Peter Brunner-La Rocca; Peter T Buser; Peter Rickenbacher; Patrick Hunziker; Christian Mueller; Raban Jeger; Franziska Bader; Stefan Osswald; Christoph Kaiser
Journal:  J Am Coll Cardiol       Date:  2006-11-02       Impact factor: 24.094

5.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

Authors:  Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2006-05-05       Impact factor: 24.094

6.  Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?

Authors:  Yosinobu Onuma; Patrick W Serruys
Journal:  Circulation       Date:  2011-02-22       Impact factor: 29.690

7.  Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents.

Authors:  Soji Nishio; Kunihiko Kosuga; Keiji Igaki; Masaharu Okada; Eisho Kyo; Takafumi Tsuji; Eiji Takeuchi; Yasutaka Inuzuka; Shinsaku Takeda; Tatsuhiko Hata; Yuzo Takeuchi; Yoshitaka Kawada; Takeshi Harita; Junya Seki; Shunji Akamatsu; Shinichi Hasegawa; Nico Bruining; Salvatore Brugaletta; Sebastiaan de Winter; Takashi Muramatsu; Yoshinobu Onuma; Patrick W Serruys; Shigeru Ikeguchi
Journal:  Circulation       Date:  2012-04-16       Impact factor: 29.690

8.  Systemic inflammation after drug-eluting stent placement.

Authors:  Prospero B Gogo; David J Schneider; Matthew W Watkins; Edward F Terrien; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

9.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries.

Authors:  W J van der Giessen; A M Lincoff; R S Schwartz; H M van Beusekom; P W Serruys; D R Holmes; S G Ellis; E J Topol
Journal:  Circulation       Date:  1996-10-01       Impact factor: 29.690

10.  Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent.

Authors:  Jin Won Kim; Soon Yong Suh; Cheol Ung Choi; Jin Oh Na; Eung Ju Kim; Seung-Woon Rha; Chang Gyu Park; Hong Seog Seo; Dong Joo Oh
Journal:  JACC Cardiovasc Interv       Date:  2008-02       Impact factor: 11.195

View more
  2 in total

1.  High coronary calcium score and post-procedural CK-MB are noninvasive predictors of coronary stent restenosis.

Authors:  Jae-Beom Lee; Yun-Seok Choi; Woo-Baek Chung; Ami Kwon; Chul-Soo Park; Man-Young Lee
Journal:  Clin Interv Aging       Date:  2017-02-17       Impact factor: 4.458

2.  Curcumin exerts anti-inflammatory and vasoprotective effects through amelioration of NFAT-dependent endothelin-1 production in mice with acute Chagas cardiomyopathy.

Authors:  Matías Hernández; Susana Wicz; Miguel H Santamaría; Ricardo S Corral
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-07-16       Impact factor: 2.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.